Neutrophil-Derived Cathelicidin Promotes Adhesion of Classical Monocytes

Sarawuth Wantha1,2, Jean-Eric Alard1, Remco TA Megens1, Anne M. van der Does3, Yvonne Döring1, Maik Drechsler1, Christine T.N. Pham4, Ming-Wei Wang5, Ji-Min Wang6, Richard L. Gallo7, Philipp von Hundelshausen1, Lennart Lindbom3, Tilman Hackeng8, Christian Weber1,8,9, Oliver Soehnlein1,9,10

1IPEK, LMU, Munich, GER; 2IMCAR, RWTH Aachen, GER; 3Department of Physiology, Karolinska Institutet, Stockholm, SWE; 4Department of Medicine, Washington University, St Louis, MO, USA; 5National Center for Drug Screening, Shanghai, CN; 6Laboratory of Molecular Immunoregulation, NCI, Frederick, MD, USA; 7Department of Medicine, University of California at San Diego, La Jolla, USA; 8CARIM, University Maastricht, NL; 9Munich Heart Alliance, Munich, GER; 10Department of Pathology, Academic Medical Center Amsterdam, University of Amsterdam, NL.

Running title: Cathelicidins Induce Monocyte Adhesion

Subject codes:
[97] Other vascular biology
[98] Other research

Address correspondence to:
Dr. Oliver Soehnlein
Institute for Cardiovascular Prevention (IPEK)
LMU Munich
Pettenkoferstr. 9
80336 Munich
Phone +49-(0)89-5160-4673
Fax +49-(0)89-5160-4352
oliver.soehnlein@gmail.com

In December 2012, the average time from submission to first decision for all original research papers submitted to Circulation Research was 14.5 days

DOI: 10.1161/CIRCRESAHA.112.300666
ABSTRACT

**Rationale:** The leukocyte response in acute inflammation is characterized by an initial recruitment of neutrophils preceding a second wave of monocytes. Neutrophil-derived granule proteins were suggested to hold an important role in this cellular switch. The exact mechanisms by which neutrophils mediate these processes are only partially understood.

**Objective:** To investigate the role of neutrophils and their granule contents in the adhesion of monocyte subpopulations in acute inflammation.

**Methods and Results:** Here, we show that neutrophil-derived cathelicidins (human: LL37, mouse: CRAMP) induce adhesion of classical monocytes but not of non-classical monocytes in the mouse cremaster muscle and in *in vitro* flow chamber assays. CRAMP is released from emigrated neutrophils and then transported across the endothelium where it is presented to rolling leukocytes. Endothelial-bound cathelicidin activates FPR2 on classical monocytes, resulting in monocytic β1- and β2-integrin conformational change towards an extended, active conformation that allows for adhesion to their respective ligands VCAM-1 and ICAM-1.

**Conclusions:** These data elucidate a novel mechanism of neutrophil-mediated monocyte recruitment, which could be targeted in conditions where recruitment of classical monocytes plays an unfavorable role.

**Keywords:** Neutrophil, monocyte, inflammation, cathelicidin, recruitment, chemokine

**Non-standard Abbreviations:**
- DARC: Duffy antigen/receptor for chemokines
- FPR: Formyl-peptide receptor
- HUVEC: Human umbilical vein endothelial cells
- PMA: Phorbol-12-myristate-13-acetate
- WT: Wild type

INTRODUCTION

Neutrophils dominate the initial wave of leukocytes emigrating into inflamed tissues (1). This first wave of neutrophil extravasation precedes a second wave of monocyte extravasation. Recruited neutrophils are thought to contribute to this cellular switch by several mechanisms (2,3) including the release of soluble factors like neutrophil granule proteins which are deposited at the site of inflammation (4). Indeed, supernatants of activated neutrophils from patients with specific granule deficiency show a reduced capacity to attract monocytes despite normal monocyte chemotaxis *in vitro* to other stimuli (5). Following this observation, several neutrophil granule proteins with monocyte-attracting activity were identified. Among them are cathelicidin (human: LL37, mouse: CRAMP) (6), cathepsin G (7), α-defensins (8), and azurocidin (7).

Peripheral blood monocytes constitute a heterogeneous population of circulating leukocytes in both humans (9) and mice (10). Based on the expression of Gr1, classical (inflammatory, Ly6C^hi^) and non-classical (resident, patrolling, Ly6C^lo^) mouse monocytes can be discriminated. Functionally, non-classical monocytes are thought to contribute to phagocytosis, wound healing, and tissue remodeling, whereas classical monocytes dominate inflammatory processes such as the early response in infections, but also sterile inflammatory conditions such as myocardial infarction or atherosclerosis (11). In humans, monocyte subsets are discriminated based on their CD14 and CD16 expression profile with classical monocytes being CD14^+^CD16^−^, intermediate monocytes being CD14^+^CD16^+^, and nonclassical monocytes being CD14^−^CD16^+^ (12).
While several studies have shown the important chemotactic activities of neutrophil granule proteins towards monocytes, the role of neutrophil secretory products in early steps of monocyte recruitment have not been studied. Hence, we here investigated the role of neutrophils and their granule constituents in their capacity to differentially induce adhesion of monocyte subsets.

METHODS

For detailed Materials and Methods, please see the supplemental materials.

Mice.
Wild-type C57BL/6 and gene-targeted Lysmgfp/gfp (13), Cx3cr1εGFP/+ (14), Cramp−/− (15), Fpr1−/− (16), Fpr2−/− (17), CG−/− (18), Darc−/− (19), and Cav1−/− (20) mice were used for in vivo experiments. All genetically modified animals were on C57BL/6 background. Specific neutrophil depletion was achieved by intraperitoneal injection of monoclonal antibody 1A8 (50 μg/mouse, BioXCell) 8h before injection of the stimuli (Online Table I). All animal experiments were approved by the local ethical committee for animal experimentation.

RESULTS

Cathelicidin induces firm adhesion of classical monocytes.
To study the importance of neutrophils in the adhesion of monocytes we injected TNF into the cremaster of Cx3cr1εGFP/wt mice carrying green fluorescent monocytes and recorded the adhesion of monocytes in vivo. To discriminate between classical monocytes and non-classical monocytes, an antibody to Ly6C was introduced which labels classical monocytes (Online Figure I). In these experiments neutropenic mice displayed reduced adhesion of classical monocytes (Ly6C+/gfp+) to postcapillary venules, whereas rolling flux of classical monocytes was increased (Figure 1A,B). In contrast, adhesion of non-classical monocytes (Ly6C−/gfp+) remained unaffected (Figure 1A,C). With the reported importance of neutrophil granule proteins in the recruitment of monocytes (4) we aimed at addressing the role of granule proteins in monocyte adhesion. Neutrophil-derived azurocidin, cathepsin G, α-defensins, and cathelicidins have been suggested to be involved in neutrophil-dependent monocyte activation (2,3). As azurocidin and defensins are absent in mouse neutrophils (21,22), we focused on the role of cathepsin G and cathelicidin in neutrophil-mediated monocyte adhesion. Adhesion of classical monocytes in TNF-stimulated cremaster muscles was impaired in cathelicidin-deficient (Cramp−/−) mice when compared to wild type (WT) control animals, a response not further aggravated by neutrophil depletion (Figure 1D). In contrast, cathepsin G-deficient (CG−/−) mice exhibited no impaired adhesion of classical monocytes (Figure 1D). In line, neutrophil depletion reduced classical monocyte adhesion in CG−/− mice indicating that not cathepsin G but CRAMP is relevant for neutrophil-dependent monocyte adhesion.

To further corroborate our findings with human monocyte subsets, we performed in vitro flow chamber assays. Human classical CD14++CD16− (Figure 1F) and non-classical CD14−CD16++ monocytes (Figure 1G) were perfused over human umbilical vein endothelial cells (HUVEC). Adhesion of either subset was enhanced when HUVEC were activated with TNF. However, deposition of LL37 on HUVEC 15min prior to monocyte perfusion specifically enhanced adhesion of classical CD14++CD16− monocytes. As treatment of HUVEC with LL37 did not impact on expression of endothelial adhesion molecules (Online Figure II), we concluded that the LL37-mediated increase in monocyte adhesion is not achieved by modulating endothelial cell adhesion molecule expression.
Neutrophil-derived cathelicidin is transported in a baso-apical direction across the endothelium.

To study the dynamics of cathelicidin release and in vivo presentation, we injected monocyte-depleted Lysm^GFP/GFP mice (thus creating mice with fluorescent neutrophils only) with TNF intrascrotally and recorded the adhesion and extravasation of neutrophils. In addition, microbeads conjugated with an antibody to CRAMP were injected to visualize endothelial bound CRAMP (Figure 2A). While adhesion of neutrophils occurred rapidly and peaked at 2h, endothelial-bound CRAMP was not detected in significant numbers until 4h after TNF stimulation thus correlating more closely with the number of emigrated neutrophils (Figure 2B,C). Detection of endothelial CRAMP peaks between 4 and 12h after TNF injection. During this time, neutrophil adhesion decreases, whereas the number of emigrated neutrophils reaches its maximum (Figure 2B,C). Depletion of neutrophils reduced the number of adherent anti-CRAMP-conjugated microbeads to a level observed in Cramp^-^- mice thus confirming that CRAMP in this location is neutrophil derived (Figure 2D). To further investigate alternative CRAMP sources, we analyzed intracellular CRAMP expression in endothelial cells and in neutrophils obtained from enzymatically digested cremaster muscles. To discriminate between adherent and extravasated neutrophils an antibody to Ly6G was injected intravenously 5 minutes prior to sacrifice (23). In these experiments, minor amounts of CRAMP were detected in endothelial cells (figure S3). In contrast, we detected large amounts of CRAMP in adherent neutrophils that were decreased in emigrated neutrophils, suggesting discharge of CRAMP following emigration (Online Figure III).

Since our in vivo experiments suggested that cathelicidins are transported across the endothelium in a baso-apical direction, we aimed at studying such mechanism in vitro. HUVEC were grown on tissue culture filter inserts and stimulated with TNF. FITC-LL37 was added to the bottom well and LL37 transportation was assessed by two-photon microscopy. In these experiments LL37 was found to accumulate on the endothelial cell surface (Figure 2E). To quantify the amount of transcytosed LL37 we assessed the fluorescence resulting from antibody-stained, surface-bound LL37. In time course experiments we found that LL37 accumulated on the HUVEC surface not until 2h (figure 2F). The transendothelial transportation was abrogated at 4°C (Figure 2G) and by pretreatment with colchicine or cytochalasin B (Figure 2H). Cathelicidins were reported to act through FPR2, CXCR2, and P2X7 (7,24,25). However, pretreatment of HUVEC with boc-PLPLP (antagonist to FPRs), SB225002 (antagonist to CXCR2), or suramin (antagonist to P2X7) did not impact on transendothelial LL37 transportation (Figure 2H). As highly cationic polypeptide, we suspected that LL37 might interact with endothelial proteoglycans. To this end we cleaved endothelial heparansulfate or chondroitinsulfate side chains by use of heparinase or chondroitinase and recorded its effect on LL37 transcytosis. Interestingly, pretreatment with either enzyme markedly reduced the transendothelial transportation across the endothelium (Figure 2H). Finally, targeting caveolae-mediated transportation by pre-treatment with filipin resulted in clear-cut decreases of LL37 transcytosis. Since duffy antigen/receptor for chemokines (DARC) facilitates transport of chemokines across the endothelium (26) we also wanted to address its involvement in the transendothelial transportation of CRAMP. However, in our hands HUVEC activated with TNF did not express DARC and we could not detect an interaction between DARC and LL37 (Online Figure IV).

We next injected CRAMP intrascrotally into neutropenic WT mice and detected its luminal appearance by intravital microscopy. In WT mice luminal CRAMP was detected 4h after intrascrotal CRAMP injection, a response abrogated in caveolin 1-deficient (Cav^-^-) mice (Figure 2I). Immobilisation of anti-CRAMP microbeads was not seen when PBS was used instead of CRAMP (not shown). However, the transportation of CRAMP across the endothelium was maintained in Darc^-^- mice.

Cathelicidin-dependent recruitment requires FPR2 activation on monocytes.

Cathelicidins were reported to activate target cells through various receptors including FPR2, CXCR2, and P2X7. To find out which of these receptors is relevant in cathelicidin-mediated adhesion of classical monocytes, we performed in vitro flow chamber assays (Figure 3A). Monocytes were pre-treated with suramin, SB225002, or boc-PLPLP and perfused over TNF-activated HUVEC. While all
antagonists were without effects when classical CD14++CD16 monocytes were perfused over TNF-activated HUVEC, boc-PLPLP specifically abrogated LL37-mediated increases in classical CD14++CD16 monocyte adhesion. Since boc-PLPLP blocks activation of all FPR family members we further used specific antagonists to FPR1 and FPR2. In these experiments, the FPR2 specific antagonist quin-C7 (Figure 3A) but not the FPR1-specific antagonist spinorphin (not shown) abrogated LL37-dependent adhesion of classical CD14++CD16 monocytes.

We further suspected that differences in FPR2 expression levels between monocyte subsets may explain the specificity of LL37 in enhancing adhesion of classical monocytes but not of non-classical monocytes. Analysis of FPR2 expression revealed that FPR2 is expressed to a higher degree on classical CD14++CD16 monocytes as compared to non-classical CD14+CD16+ monocytes (Figure 3B), thus offering an explanation for the specificity of cathelicidin-dependent adhesion. Furthermore, the FPR2 expression on CD14++CD16 monocytes (MFI 614±27) was intermediate, falling in between the FPR2 expression on classical and non-classical monocytes. In line with these observations, classical monocytes in mice also carry higher levels of FPR2 when compared to their non-classical counterpart (Figure 3C). As few data exist on direct interaction of LL37 with its putative receptors, we aimed at analyzing the interaction of LL37 and FPR1, FPR2, CXCR2, and P2X7 biochemically. For this we performed surface plasmon resonance experiments employing recombinant receptors expressed in proteoliposomes thus maintaining the three dimensional chemokine receptor structure. LL37 was immobilized on a CM4 chip and superfused with receptor-containing proteoliposomes (Figure 3D). With this approach we were able to detect a clear binding of LL37 to FPR2, while the interaction with FPR1 or CXCR2 was not different when compared to empty liposomes. For P2X7 we found no interaction with LL37 (not shown).

To further investigate if cathelicidin-mediated monocyte adhesion in vivo depends on employment of FPR2, we injected CRAMP along with TNF into the scrotum of neutropenic WT mice. Receptor utilization was initially studied by use of antagonists to FPRs, P2X7, and CXCR2. In these experiments inhibition of FPRs by quin-C7 clearly reduced CRAMP-mediated adhesion, while the other antagonists were without effects (Figure 3E). To further corroborate this, we injected neutropenic Fpr1−/− or Fpr2−/− mice with TNF and CRAMP. While CRAMP injection resulted in increased adhesion in Fpr1−/− mice, this response was not observed in Fpr2−/− mice (Figure 3E).

Cathelicidins induce integrin activation on classical monocytes.

Thus far we have shown that neutrophil-derived cathelicidins resemble a functional similarity with arrest chemokines (27). The latter mediate firm adhesion through inside-out integrin signaling and subsequent changes in integrin conformation towards an extended, high affinity state. Classical ligands for VLA4 (CD49d/CD29, α4β1 integrins) and Mac1 (CD11b/CD18, αMβ2 integrin) are VCAM-1 and ICAM-1, respectively. To test the importance of these two ligands for LL37-mediated adhesion we perfused classical CD14++CD16+ monocytes over plates coated with P-selectin/ICAM-1 or P-selectin/VCAM-1 (Figure 4A,B). In these experiments coimmobilization of LL37 or MCP1 strongly enhanced monocyte adhesion. This response was fully abrogated by a blocking antibody to CD11b or CD49d. While the LL37-dependent monocyte adhesion was abolished in presence of an inhibitor to FPR2, the MCP1-mediated adhesion of monocytes was blocked by an antagonist to CCR2. To further investigate the activation of β1- and β2-integrins by LL37, we used an antibody that specifically recognizes the extended conformation of these integrins. Monocytes were incubated with PMA, MCP1, or LL37 and stained for the expression of active integrins. While PMA induces integrin activation on both monocyte subsets, MCP1 and LL37 only induce significant integrin activation on classical CD14++CD16 (Figure 4C) and intermediate CD14+CD16+ (Figure S5) monocytes but not on non-classical CD14+CD16− monocytes (Online Figure V). Similarly, PMA, MCP1, or CRAMP induced integrin activation on murine classical but not non-classical monocytes leading to increased binding of ICAM-1 or VCAM-1 (Figure 4D and Online Figure VI). In line with the adhesion experiments, antagonists to P2X7, CXCR2, and FPR1 failed to block LL37-dependent integrin activation (not shown), whereas antagonists to FPR2 fully abrogated integrin activation induced by LL37 (Figure 4E,F). In addition, we tried to elucidate if LL37 and MCP1 employ similar intracellular pathways that lead to integrin activation. To this end, monocytes were pre-treated with inhibitors to
phospholipase C (PLC), which is crucial in chemokine-mediated activation of β2-integrins (28). PLC blockage reduced LL37- and MCP1-induced integrin activation on classical monocytes (Figure 4E,F). In contrast, blockade of bruton-tyrosine kinase (BTK) or Syk kinase, which are required for selectin-dependent integrin activation (28), failed to block ligand-induced integrin activation (not shown).

Mutation of LL37 abrogates its arrest function.

To identify the motif within LL37 that interacts with FPR2, we compared the amino acid sequences of known FPR2 ligands including MKYMVM, MMK1, and humanin with clustal Omega software. Despite the absence of any strict amino acid homology, we found a pattern of chemical properties present in all FPR2 ligands. More precisely, an aromatic amino acid and two hydrophobic residues separated by two amino acids was the only similarity between the molecules (Figure 5A). LL37 and the other FPR2 agonists are linear peptides, which simplifies the comparison of their three-dimensional structure. In their helicoid structure with a turn of 3 amino acids the aromatic and the hydrophobic residues were nearby and can form a hydrophobic domain. To test the involvement of this pattern in LL37-dependent monocyte adhesion, we synthetized a mutated LL37 (mLL37) with an alanine instead of the phenylalanine in position 17 (F17A) and glycine in replacement of the isoleucine and the valine in position 20 and 21 (I20G and V21G) (Figure 5A).

To test the functionality of mLL37 we performed adhesion and integrin activation assays. Interestingly, mLL37 did not induce adhesion to TNF-activated HUVEC (Figure 5B) or to immobilized recombinant cell adhesion molecules (Figure 5C,D). In addition, mLL37 failed to enhance monocyte adhesion in vivo (Figure 5E) and to induce conformational changes of β1- or β2-integrin (Figure 5F,G). Thus, these data indicate the importance of the central FKRIV motif within LL37 to induce FPR2-mediated monocyte adhesion.

DISCUSSION

The data of the here presented study identify a novel neutrophil-driven mechanism of classical monocyte adhesion. Upon neutrophil tissue infiltration cathelicidin is released and transported across the endothelium involving a caveolin 1-mediated transportation process. Cathelicidins are then presented to cells rolling along the endothelium. Classical monocytes recognize endothelial-bound cathelicidins via FPR2. This interaction triggers an intracellular signaling cascade involving PLC ultimately leading to activation of monocytic β1- and β2-integrins and subsequent adhesion of classical monocytes.

Monocyte subsets harbor crucial albeit differential functions during inflammation. Classical monocytes originate from the bone marrow and spleen to accumulate at sites of inflammation, where they differentiate into macrophages (29). In the absence of inflammation, classical monocytes are thought to convert into non-classical monocytes, although this is still under debate (30). Non-classical monocytes patrol the luminal side of post-capillary venules, where they sense damage or infection (31) and trigger inflammatory reactions. However, here we show that classical but not non-classical monocytes sense cathelicidins, which are known to be potent danger signals (32), and subsequently adhere to the endothelial lining. Classical monocytes exert potent pro-inflammatory functions including release of reactive oxygen species, TNF, IL-6, and type I interferons, which have been identified as powerful proinflammatory mediators (11). In addition, classical monocytes disturb the resolution of inflammation (33) thus perpetuating inflammatory processes.

With the discovery of monocyte subsets, a concept has emerged wherein the relative expression of adhesion molecules or chemokine receptors governs their recruitment behavior. In this context, it was shown that classical monocytes utilize CCR2, CX3CR1, CXCR2 as well as CCR5 to adhere and migrate to inflammatory sites (34). Similarly, PSGL-1 is expressed to a higher degree on classical monocytes and was hence found to be a major determinant in their recruitment (35). In the here presented study we demonstrate that FPR2 is dominantly expressed on classical monocytes and
almost absent on non-classical monocytes hence explaining the exclusive adhesion of classical monocytes in response to immobilized cathelicidins. In addition, recent studies point towards the importance of FPR1 in the recruitment and locomotion of neutrophils towards danger signals (36,37). Thus, it remains to be identified how FPR1 ligands differentially affect adhesion and recruitment of monocyte subsets.

Beyond the induction of classical monocyte adhesion as shown here, cathelicidins may promote monocyte recruitment through direct and indirect chemotactic effects. The direct chemotactic effect is primarily mediated via FPR2 with a maximum activity at concentrations of 0.5-50µg/ml (0.1-10µM) (4,6,38). Notably, the direct chemotactic activity of LL37 is not affected by serum (6), thus contrasting the effects of serum on the microbicidal effects of LL37 (39). This discrepancy may be due to the fact that the chemotactic activity is receptor-mediated and not dependent on a peptide-membrane interaction. Presumably, the part of the LL37 peptide that activates FPR2 is not hidden or altered by association of serum components, indicating that recruitment of leukocytes by LL37 is an important biological mechanism that is maintained along the vascular lumen. Besides its direct chemotactic activities, cathelicidins contribute to the inflammatory accumulation by stimulation of chemokine and cytokine production through effector cells. In this context, LL37 induces the production and release of IL8 from monocytes (40). In addition, LL37 was also shown to interact with the purinergic receptor P2X7, a receptor that is predominantly expressed on monocytes, macrophages and dendritic cells. LL37-stimulation via P2X7 of LPS-primed monocytes induced processing and release of the potent cytokine IL-1β (41). This proinflammatory cytokine upregulates adhesion molecules on endothelial cells and hence promotes leukocyte adhesion.

Fundamental to the accumulation of monocytes and macrophages at sites of inflammation is, however, not just their recruitment but also the control of their mobilization from sites of production as well as their survival at the inflammatory site (42). Since counts of circulating leukocyte subsets are not altered in Cramp−/− mice (43) it is to be assumed that cathelicidins do not play a role in the mobilization of monocytes from the bone marrow. In contrast, cathelicidins were shown to exert divergent effects on apoptotic cell death. While LL37 promotes apoptosis in various T-cells, smooth muscle cells, and epithelial cells (44,45), it was shown to inhibit apoptotic cell death in neutrophils (24). A consequence of the inhibition of apoptosis of neutrophils may be a survival strategy, leading to an increase of viable neutrophils at the site of infection, which is beneficial for the host during bacterial invasion. Although such data are not readily available for monocytes one may assume that similar mechanisms could contribute to the cathelicidin-mediated accumulation of monocytes at sites of inflammation.

As detailed above, cathelicidin-dependent mechanisms of monocyte adhesion, chemotaxis, and homeostasis may promote accumulation of classical monocytes at inflammatory sites. That such mechanisms importantly contribute to monocyte accumulation is indicated by observations from air pouch models where the instillation of cathelicidins results in pronounced accumulation of monocytes (4,46). In diseases models of vascular inflammation, lack of CRAMP reduces the adhesion of classical monocytes as well as the number of macrophages in atherosclerotic lesions (43). In a model of arterial injury, neutrophil-derived CRAMP was found to promote adhesion of angiogenic monocytes thereby limiting neointima formation (47). In addition, CRAMP-deficient mice exhibit reduced accumulation of classical monocytes into the lungs of mice treated with hypo-chloric acid or LPS (unpublished data) and into the peritoneum upon stimulation with TNF, the latter being rescued by local application of CRAMP (unpublished data). Taken together, CRAMP may be an important facilitator of the accumulation of classical monocytes at sites of inflammation independently of the underlying stimulus. Since the chemotactic activity of cathelicidins is independent of receptors that are typically employed by classical chemokines (e.g. CCR2 for CCL2/MCP-1), we suspect that cathelicidins exert a non-redundant role in the extravasation of monocytes. In line with this concept, intracellular Ca2+ mobilization in response to neutrophil secretory products is conserved in Cer2−/− classical monocytes (4). This notion along with the fact that many chemokines require de novo synthesis, whereas granule proteins are in general preformed led us to propose a concept where the initial monocyte efflux is primarily mediated by alarmins (i.e. preformed proteins with chemotactic activity) whereas later phases of monocyte emigration rely on chemokines (2).
Since CRAMP was found abundantly in adherent neutrophils and to far lesser extend in emigrated neutrophils, we conclude that neutrophils are the primary source of cathelicidins in the inflammation model employed in this study. However, tissue-resident cells such as endothelial cells which carry lower amounts of CRAMP may contribute to luminal CRAMP. The primary importance of neutrophil-derived CRAMP in leukocyte adhesion is further supported by a study showing that mice reconstituted with Cramp-/- bone marrow but not with WT bone marrow exhibit reduced adhesion of monocyctic, angiogenic cells (47).

The here unraveled process of cathelicidin transendothelial transportation and monocyte activation offers various possibilities for therapeutic interference. Caveolin 1 mediates transportation of chemokines such as MCP1 across endothelium hence being an important facilitator of leukocyte adhesion (48). In atherosclerosis, mice lacking caveolin 1 exhibit strongly reduced atherosclerotic lesion sizes along with lower amounts of MCP1 presented on the endothelium as well as fewer adherent and transmigrating monocytes (49) thus implying that caveolin 1-dependent shuttling of chemokines is relevant to inflammatory pathologies like atherosclerosis. As similar observations regarding monocyte adhesion and recruitment are made in atherosclerotic Cramp-deficient mice (43), caveolin 1-mediated transportation of cathelicidins may not just occur in the microcirculation as shown here but also in large arteries. Hence tissue-specific targeting of such process may be an interesting approach to control the accumulation of classical monocytes.

Previous studies have shown that the antimicrobial activity of cathelicidin resides within specific domains that are different from the immune cell activating domains (50). Lack of cathelicidins in humans or mice favors the onset of infections and impairs monocyte recruitment (5,15). This study provides evidence for the importance of the central FKRIV motif in FPR2-dependent adhesion of classical monocytes. Several groups have studied the involvement of specific amino acid domains in the LL37 sequence responsible for its antimicrobial (51) or other immunomodulatory effects (52) usually resulting in a LL37-derived peptide sequence with the FKRIV motif present in it. Even though the role of FPR2 was not investigated in these studies, our findings show that strategies specifically preventing the LL37-FPR2 interaction could be applicable in treatment of inflammatory processes where recruitment of classical monocytes plays a non-favorable role.

Taken together, our data provide a novel mechanism of monocyte recruitment involving the interaction of neutrophil-derived cathelicidin and monocyctic FPR2. Therapeutic interference with transendothelial cathelicidin transportation, its endothelial presentation, or the cathelicidin-FPR2 interaction may be beneficial in circumstances where recruitment of classical monocytes plays an unfavorable role.

ACKNOWLEDGMENTS
The authors would like to thank Patricia Lemnitzer for excellent technical assistance, Markus Sperandio for critical data discussion, Philip M. Murphy for providing Fpr1-/- mice, and Antal Rot for DARC-MDCK cells.

SOURCES OF FUNDING
This study was supported by the German Research Foundation (SO876/3-1, SO876/4-1, HU1618/1-2, SFB914 TPB08), the German-Israeli Foundation, the Else Kröner Fresenius Stiftung, the NWO (VIDI project 91712303), and the ERC (Advanced Grant 249929). J.E.A. is recipient of a postdoctoral scholarship from the Alexander von Humboldt Foundation.

DISCLOSURE
The authors declare no competing financial interests.

DOI: 10.1161/CIRCRESAHA.112.300666
References


FIGURE LEGENDS

Figure 1: Neutrophil-derived cathelicidin enhances adhesion of inflammatory monocytes. A-C: Neutropenia reduces adhesion of classical monocytes. Cx3cr1<sup>fl/fl</sup>/WT mice with intact white blood cell count or neutropenia (1A8, 50µg i.p., 12h prior to experiment) were injected intrascrotally with TNF (50ng, 12h). To discriminate between monocyte subsets an antibody to Ly6C (1µg) was introduced i.v. A: Representative images, classical monocytes appear in yellow, non-classical monocytes appear in green, scale bar 20µm. B: Adhesion and rolling flux of classical monocytes. * significant difference from respective control. C: Adhesion of non-classical monocytes. n=6. D: Comparison of adhesion of Ly6C-labeled classical monocytes in indicated mouse strains with intact white blood cell count or neutropenia following intrascrotal TNF injection (50ng, 12h). * significant difference compared to wild type (WT) mice with intact white blood cell count. n=6. E: Intrascrotal injection of CRAMP in Cramp<sup>−/−</sup> mice restores adhesion of classical monocytes. Cramp<sup>−/−</sup> were intrascrtoally injected with TNF (ctrl) or with TNF and CRAMP (CRAMP, 1µg). Adhesion of Ly6C-labeled classical monocytes was assessed by intravital microscopy. n=6. Representative images are shown. Scale bar 20µm. F/G: Human classical CD14<sup>+</sup>CD16<sup>+</sup> (F) or non-classical CD14<sup>+</sup>CD16<sup>+</sup> monocytes (G) were perfused over TNF-activated (20ng, 12h) HUVEC monolayer and the number of adherent cells was quantified. LL37 (1µg) was deposited 15 min prior to perfusion. n=6. * significant difference compared to TNF-activated HUVEC.

Figure 2: Neutrophil-derived cathelicidin is transported in a baso-apical direction across the endothelium. A-C: Luminal CRAMP accumulation parallels with neutrophil extravasation but not neutrophil adhesion. Lysm<sup>−/−</sup> mice were intrascrtoally injected with TNF (50ng) and the adhesion (B, green line) and transmigration (C, green line) of neutrophils was quantified by intravital microscopy at indicated time points. To assess luminal CRAMP presentation, immobilization of G-protein coupled fluorescent beads conjugated with an antibody to CRAMP was analysed (red line in B and C). n=4 for each data point. Representative images for indicated time points are shown in A. For better visibility, immobilized beads were marked with red dots. Scale bar, 50µm. D: Wild type (WT) or Cramp<sup>−/−</sup> mice with intact white blood cell count (WBC) or neutropenia were intrascrtoally injected with TNF (50ng, 12h). Luminal CRAMP presentation was assessed after injection of G-protein coupled fluorescent beads conjugated with antibodies to CRAMP. * indicates significant difference compared to respective mouse strain with intact WBC. n=5. E: LL37 is transported across HUVEC grown on transwell filter inserts. LL37 was added to the bottom well and analyses were made 4h later by 2-photon microscopy. LL37 (green) was visualized by a fluorescent tag (top) or by antibody staining of non-permeabilized endothelial cells (bottom). Cell membrane, red; Nucleus, blue. F: Antibody detection of transcytosed LL37 on the apical side of endothelial cells in time course experiments. G/H: Transcytosis experiments performed at 4 °C (G) or by pretreatment of endothelial cells with indicated inhibitors (H). n=6 for each bar. * significant difference from ctrl. I: CRAMP transportation is impaired in Cav1<sup>−/−</sup> mice. Neutropenic WT, Darc<sup>−/−</sup>, or Cav1<sup>−/−</sup> mice were intrascrtoally injected with TNF (50ng, 4h) and CRAMP (1µg). Luminal CRAMP presentation was assessed after injection of G-protein coupled fluorescent beads conjugated with an antibody to CRAMP. Scale bar is 20µm in representative images. * significant difference compared to wild type mice. n=4.

Figure 3: Cathelicidin-induced monocyte adhesion requires FPR2. A: Human classical CD14<sup>+</sup>CD16<sup>+</sup> monocytes were perfused over TNF-activated (20ng, 12h) HUVEC and the number of adherent cells was quantified. LL37 (1µg) was deposited 15 min prior to perfusion. Monocytes were left untreated (ctrl) or were pretreated for 15 min with SB225002 (blocks CXCR2, 100nM), suramin (blocks P2X7, 100nM), boc-PLPLP (blocks FPRs, 100nM), or quin-C7 (blocks FPR2, 1µM). * significant difference compared to respective control. n=8. B/C: FPR2 expression was analysed on human (B) or mouse (C) classical and non-classical monocytes using flow cytometry. Representative histograms in B display staining with isotype control IgG (orange) and a FPR2 antibody (green). D: Representative surface plasmam resonance sensorgrams of binding of indicated receptors expressed in proteoliposomes to immobilized LL37 on a CM4-sensorchip. Empty proteoliposomes were used as control. E: Wild type (WT), Fpr1<sup>−/−</sup>, or Fpr2<sup>−/−</sup> mice were rendered neutropenic and injected with TNF (ctrl) or with TNF and CRAMP (CRAMP, 1µg). Antagonists to CXCR2 (SB225002, 5mg/kg), P2X7 (suramin, 10mg/kg), and FPR2 (quin-C7, 10mg/kg) were administered i.v. 30 minutes prior to intravital microscopy at indicated time points. To assess luminal CRAMP presentation, immobilization of G-protein coupled fluorescent beads conjugated with an antibody to CRAMP was analysed (red line in B and C). n=4 for each data point. Representative images for indicated time points are shown in A. For better visibility, immobilized beads were marked with red dots. Scale bar, 50µm.

DOI: 10.1161/CIRCRESAHA.112.300666
recording. Adhesion of Ly6C-labeled classical monocytes was assessed by intravital microscopy. n=6 for each bar. * significant difference compared to respective control group, ** significant difference compared to CRAMP-treated WT mice.

**Figure 4: Cathelicidins induce integrin activation.** A/B: LL37 mediates Mac1 (CD11b/CD18) and VLA4 (CD49d/CD29) dependent adhesion. Classical CD14++CD16 monocytes were perfused over P-selectin/ICAM-1 (A) or P-selectin/VCAM-1 (B) coated dishes. The increase in adhesion by coin mobilization of LL37 or MCP1 was set to 100%. Classical CD14++CD16 monocytes were pretreated with anti-CD11b (1µg/ml), anti-CD49d (1µg/ml), or antagonists to FPR2 (quin-C7, 1µM) or to CCR2 (RS504393, 1µM). n=8. * significant difference compared to ctrl. C: Based on the CD16 and CD14 staining properties, human monocyte subsets were identified within peripheral blood mononuclear cells. Moreover, antibodies to activation epitopes of VLA4 (HUTS-21) and CD11b (CBRM1/5) were added. Cells were treated with PMA (50ng/ml), MCP-1 (50ng/ml), or LL37 (1µg/ml) for 15 min and the expression of activated CD11b (left) or VLA4 (right) was assessed on classical CD14++CD16 monocytes. * significant difference from control group. n=6. D: CRAMP activation enhances ICAM-1 and VCAM-1 binding to classical monocytes. Mouse peripheral leukocytes were treated with PMA (50ng/ml), MCP-1 (50ng/ml), or CRAMP (1µg/ml) in the presence of ICAM-1-Fc (left) or VCAM-1-Fc (right) and an anti-Fc antibody. Monocyte subsets were identified by additional antibody staining (CD45, CD11b, CD115, Gr1). * significant difference from control group. n = 5. E/F: Expression of activated CD11b (E) or VLA4 (F) on classical CD14++CD16 monocytes in response to LL37 (1µg/ml) or MCP1 (50ng/ml) was set to 100%. PBMCs were pretreated with antagonists to PLC (U73122, 100nM), FPR2 (quin-C7, 1µM) or CCR2 (RS504393, 1µM). n=4. * significant difference compared to respective control group.

**Figure 5: Mutation of LL37 abrogates its adhesive capacity.** A: Alignment of amino acid sequence of known FPR2 ligands, LL37, and mutated LL37 (mLL37). B: Human classical CD14++CD16 monocytes were perfused over TNF-activated (20ng, 12h) HUVEC and the number of adherent cells was quantified. LL37 (1µg) or mLL37 (1µg) were deposited 15 min prior to perfusion. * significant difference compared to control. n=5. C/D: Classical CD14++CD16 monocytes were perfused over P-selectin/ICAM-1 (C) or P-selectin/VCAM-1 (D) coated dishes. In addition, LL37 or mLL37 were coimmobilized. n=3. * significant difference compared to ctrl. E: Wild type mice were rendered neutropenic and injected with TNF (ctrl) or with additional LL37 (1µg) or mLL37 (1µg). Adhesion of Ly6C-labeled classical monocytes was assessed by intravital microscopy. n=5. * significant difference compared to control. F/G: Activation of CD11b (F) or VLA4 (G) in response to PMA (50ng/ml), LL37 (1µg/ml), or mLL37 (1µg/ml) was assessed by flow cytometry. n=6. * significant difference compared to control.
Novelty and Significance

What Is Known?

- An acute inflammatory response is characterized by neutrophil infiltration that precedes the recruitment of classical monocytes.
- Activated neutrophils secrete granule proteins that not only exert antimicrobial activities, but also instruct immune cells.
- Cathelicidins (CRAMP in mouse, LL37 in humans) have potent effects on the recruitment and the activation of immune cells, such as monocytes and dendritic cells.

What New Information Does This Article Contribute?

- Neutrophils contribute to the adhesion of classical monocytes; an effect that is in part mediated by neutrophil-derived CRAMP.
- CRAMP is released from emigrated neutrophils and then transported across the endothelium to be presented to monocytes rolling along the endothelium.
- CRAMP induces adhesion of classical monocytes by ligating FPR2.
- CRAMP-induced FPR2 activation induces conformation changes that lead to the activation of integrins.

During acute inflammation, emigrating neutrophils contribute to monocyte recruitment, but underlying mechanisms remain unclear. Activated neutrophils secrete pre-formed granule proteins, some of which recruit and activate immune cells. This study shows that neutrophil-derived cathelicidin is secreted by emigrated neutrophils, transported across the endothelium in a Caveolin 1-dependent manner and presented on the luminal side of the endothelium towards monocytes rolling along the endothelium. Cathelicidin bound to the endothelium is recognized by formyl-peptide receptor 2 (FPR2), which is expressed to a higher degree on classical than non-classical monocytes. This interaction leads to rapid integrin activation with subsequent adhesion of classical monocytes. Given the importance of classical monocytes in inflammation, the cathelicidin-FPR2 axis may be a novel target in the treatment of several inflammatory diseases.
Figure 1

A

intact WBC
neutropenic

B

Ly6C^hi monocytes

C

Ly6C^lo monocytes

D

WT  
C ramp^-/-  
CG^-/-

E

CD14^++CD16^- monocytes

F

CD14^+CD16^++ monocytes

G

ctrl  LL37  TNF  TNF+LL37

* **
Figure 3

(A) Adherent cells/field

(B) Human FPR2 (MFI)

(C) Mouse FPR2 (MFI)

(D) FPR2, FPR1, ctrl, CXCR2

(E) Adherent cells/field

WT

Fpr1^-/-

Fpr2^-/-
Neutrophil-Derived Cathelicidin Promotes Adhesion of Classical Monocytes
Sarawuth Wantha, Jean-Eric Alard, Remco TA Megens, Anne M van der Does, Yvonne Döring, Maik Drechsler, Christine T.N. Pham, Ming-Wei Wang, Ji-Min Wang, Richard Gallo, Philipp von Hundelshausen, Lennart Lindbom, Tilman M. Hackeng, Christian Weber and Oliver Soehnlein

Circ Res. published online January 2, 2013;
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/early/2013/01/02/CIRCRESAHA.112.300666

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2013/01/02/CIRCRESAHA.112.300666.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
Supplemental Methods

**Intravital microscopy of the cremaster muscle**
An inflammatory response was induced by intrascrotal injection of TNF (50ng). The cremaster muscle was exposed and recordings were made using an Olympus BX51 microscope equipped with a Hamamatsu 9100-02 EMCCD camera (Hamamatsu Photonics) and a 20x water dipping objective. For image acquisition and analysis Olympus cellS software (Olympus) was used. An antibody to Ly6C (ebioscience) was injected i.v. to detect adhesion of Ly6C-positive CM. For luminal detection of CRAMP presented on the endothelium, 50µl of Protein G Fluoresbrite® YG Microspheres (Polysciences) were coupled to 50µg of polyclonal Ab to CRAMP (Innovagen). Beads and antibody were reacted for 30min at room temperature, washed twice and subsequently injected i.v.

**Cell culture**
Human umbilical vein endothelial cells (HUVEC) (PromoCell) were cultured and propagated on collagen (50 µg/ml, Biochrom) coated tissue culture flask in endothelial growth medium (PromoCell). Peripheral blood mononuclear cells (PBMC) were separated by density gradient centrifugation. Monocyte subsets were then isolated using the CD16⁺ Monocyte Isolation Kit or the Monocyte Isolation Kit II (both Miltenyi Biotech Inc.) for non-classical and classical monocytes, respectively.

**Flow adhesion assay**
HUVEC cultured in petri dishes were activated with TNF (50ng/ml, 12 h, Peprotech). LL37 (1µg/ml, AnaSpec) or mutated LL37 (1µg/ml) were added 15min prior to performance of flow chamber assays. Isolated monocyte subsets were labeled with Calcein AM (Invitrogen) and perfused at 2.5dyne/cm² over HUVEC monolayers. In separate experiments, monocytes were pretreated for 30min with inhibitors detailed in the result section, washed twice and then used for flow chamber assays. Adherent cells were quantified in six randomly chosen fields.

**Transcytosis assay**
HUVECs were cultured on 24-well polycarbonate transwell filter inserts (5µm, Corning Costar) coated with collagen. HUVECs were activated with human TNF (50ng/ml, 12h, Peprotech). FITC-conjugated LL37 (10µg/ml) was added to the bottom chamber. Alternatively, native (unconjugated) LL37 (10µg/ml) was added to the lower chamber of transwells. In order to detect the transcytosed LL37 on the HUVEC cell surface, a FITC conjugated antibody against human LL37 (Innovagen) was used and the fluorescence intensity assessed by a plate reader. For visual analysis, HUVEC were then counter-stained with DAPI (nuclear dye) and CellMask (plasma membrane stain, Invitrogen) and fixed with 4% PFA at 4°C for 30min. After washing, the samples were analyzed using a Leica SP5 MP system with a water dipping 20x; NA 1.00 objective and a Ti:Sa MaiTai DeepSee laser (Spectra Physics) tuned to 790nm. Three Hybrid detectors (HyD) were spectrally tuned for optimal detection efficiency and low bleed through of signal of the used markers (HyD1: 435-485nm, HyD2: 515-550nm, HyD3: 565-630nm). Furthermore, a dye separation protocol (Leica LAS AF software) was performed for removal of any leftover bleed through of signal. Additional image preparation was performed using ImagePro 3D analyzer 7.0 (Media Cybernetics).

**Surface plasmon resonance**
Interaction between LL37 and chemotactic receptors were studied by Surface Plasmon Resonance on a Biacore X100 system (GE Healthcare). LL37 or mutated LL37 were immobilized on a CM4 sensor chip at a level of 400 response unit (RU) by amine coupling. Receptors FPR1, FPR2, CXCR2 and P2X7 (Abnova) were used as analyte and diluted in a HBS-N running buffer (0.1M HEPES, 1.5M NaCl pH 7.4). Each experiment was performed with a flow of 10µl/min with running buffer. Sensor chip surfaces were regenerated with 50mM NaOH and equilibrated with running buffer prior to the next injection. Results were analyzed with Biaevalution software.

**Integrin activation assay**
Human PBMCs were incubated 15min with PBS, PMA (50ng/ml, Sigma-Aldrich), MCP1 (50ng/ml, PeproTech), LL37 (1µg/ml, AnaSpec), or mutated LL37 (1µg/ml) and then stained with antibody against CD45, CD14, and CD16 for 30min at 4°C (BD Pharmingen). Antibodies to CD29 (HUTS-21,
BD Pharmingen) and CD11b (CBRM1/5, ebioscience) detecting epitopes of activated integrins only were used to assess integrin activation. Integrin activation was measured by flow using a FACSCanto II (BD Biosciences). The results are analyzed with FlowJo Software (Treestar).

Murine peripheral blood cells were isolated from C57Bl6 mice and suspended in Hanks Balanced Salt Solution containing 1mM CaCl$_2$ and MgCl$_2$ (Invitrogen). Cells were exposed to PMA (50ng/ml, Sigma-Aldrich), MCP1 (50ng/ml, PeproTech), CRAMP (1µg/ml, Innovagen) or an equal volume of PBS, in the presence of ICAM-1/Fc (10µg/ml, R&D Systems) or of VCAM-1/Fc (10µg/ml, R&D Systems) and PE-conjugated anti-human IgG1 (Fc-specific, Southern Biotechnology) for 5 minutes at 37°C. After washing, cells were labeled with antibodies to CD45, CD115, and Gr1 to identify monocyte subsets. Binding of ICAM-1 or VCAM-1 was measured by flow cytometry.

**Intracellular Cramp detection**

For FACS analysis of cremaster muscle single-cell suspensions, mice were injected intrascrotally with TNF (50ng, 4h). An antibody to Ly6G (1A8, 1µg) was injected 5 minutes prior to sacrifice to label adherent neutrophils. The circulation of mice was flushed with cold PBS and the muscle tissue was excised and digested with 0.25 mg/ml Liberase (Roche) in RPMI1640 + 10% FCS medium at 37 °C for 1h. Surface staining for flow cytometric analysis was conducted using combinations of antibodies against CD11b, Gr1, CD31, and CD45 (all ebioscience). Intracellular labeling of CRAMP (rabbit anti-mouse CRAMP) and an appropriate isotype control (rabbit IgG isotype control, GeneTex) was performed with IC fixation buffer and permeabilization buffer (both from ebioscience) according to the manufacturer’s protocol for staining of cytosolic proteins. Anti-rabbit IgG (ebioscience) served as fluorescently labeled secondary antibody.

**Statistics**

All data are expressed as mean±SD. Statistical calculations were performed using GraphPad Prism 5 (GraphPad Software Inc.). Mann-Whitney test, one way ANOVA with Dunnett post-hoc test, or Kruskal-Wallis test with posthoc Dunn tests were used as appropriate. * indicates a $p$-value < 0.05.
Online Figure 1: *In vivo* labeling of classical monocytes. To discriminate between monocyte subsets an antibody to Ly6C (1 µg) was introduced i.v. into *Cx3cr1*^{egfp/wt} mice. **A:** Example of intravital microscopy of the cremaster muscle using a beam splitter to allow recording of two emission wavelengths. CM, classical monocyte; NCM, non-classical monocyte. **B:** Blood was drawn from *Cx3cr1*^{egfp/wt} mice injected with an antibody to Ly6C and stained with antibodies to CD45 and CD11b. Classical monocytes (Ly6C^+gfp^+, orange) and non-classical monocytes (Ly6C^−gfp^+, green) also appear CD11b^+SSClo. In contrast, gfp^− leukocytes (grey) are either CD11b^−SSClo (neutrophils) or CD11b^−SSChi (lymphocytes). **C:** *Cx3cr1*^{egfp/wt} mice were injected i.v. with a PE-conjugated antibody to NK1.1. Labeling of NK cells was confirmed by counterstaining with an antibody to CD122 *ex vivo* (left). *In vivo*, the antibody to NK1.1 did not label adherent gfp^+ cells (right). **D:** Intravenous injection of an antibody to Ly6C efficiently labels classical monocytes. Anti-Ly6C-PE (1 µg) was introduced i.v. into *Cx3cr1*^{egfp/wt} mice. To assess *in vivo* labeling efficiency, white blood cells were counterstained *ex vivo* with antibodies to CD45, CD11b, and CD62L to allow for identification of monocyte subsets. Anti-Ly6C binding was then quantified on non-classical (I) and classical (II) monocytes.
Online Figure II: LL37 does not induce endothelial cell adhesion molecule expression. Human umbilical vein endothelial cells were treated with buffer (ctrl), LL37 (1 μg, 15 min), TNF (20 ng, 12 h), or a combination of both. Expression of E-selectin, ICAM-1, or VCAM-1 was measured by use of a fluorescence plate reader and directly conjugated antibodies towards the respective adhesion molecule. n= 3 for each bar.
Online Figure III: Neutrophils release CRAMP during extravasation. Mice were injected intrascrotally with TNF (50ng, 4h) and an antibody to Ly6G (1A8, 1µg) was injected 5 minutes prior to sacrifice to label adherent neutrophils. Cremaster muscles were excised and enzymatically digested. Intracellular CRAMP was measured in adherent and emigrated neutrophils as well as in endothelial cells. Representative histograms of three independent experiments display specific CRAMP staining as well as the respective isotype control fluorescence.
Online Figure IV: Cathelicidin does not interact with Duffy antigen/receptor for chemokines (DARC). A: TNF does not induce expression of DARC on human umbilical vein endothelial cells (HUVEC). HUVEC were treated with TNF (20 ng, 12 h) and the expression of DARC was analyzed by fluorescence plate reader. n = 3. B: LL37 does not bind to DARC. DARC-expressing Madin-Darby canine kidney (DARC-MDCK) or control MDCK cells were incubated with fluorescent LL37 at various concentrations and binding was assessed by flow cytometry. Displayed is one representative experiment.
Online Figure V: LL37 activates integrins on human intermediate but not on non-classical monocytes. Based on the CD16 and CD14 staining properties, CD14^{++}CD16^{+} intermediate monocytes (A) and CD14^{+}CD16^{++} non-classical monocytes (B) were identified within peripheral blood mononuclear cells. Moreover, antibodies to activation epitopes of VLA4 (HUTS-21) and CD11b (CBRM1/5) were added. Cells were treated with PMA (50 ng/ml), MCP-1 (50 ng/ml), or LL37 (1 µg/ml) for 15 minutes and the expression of activated CD11b (left) or VLA4 (middle) was assessed on intermediate and non-classical monocytes. Representative histograms are displayed to the right. * indicates significant difference compared to ctrl.
Online Figure VI: CRAMP does not activate integrins on murine non-classical monocytes. Mouse peripheral leukocytes were treated with PMA (50 ng/ml), MCP-1 (50 ng/ml), or CRAMP (1 µg/ml) in the presence of ICAM-1-Fc (left) or VCAM-1-Fc (right) and an anti-Fc antibody. Monocyte subsets were identified by additional antibody staining (CD45, CD11b, CD115, Gr1). n = 3. * indicates significant difference compared to ctrl.
**Online Table I: Differential leukocyte counts in mice with intact WBC and in neutropenic mice.**

All values are given in count/ml venous blood.

<table>
<thead>
<tr>
<th></th>
<th>neutrophils</th>
<th>inflammatory monocytes</th>
<th>resident monocytes</th>
<th>T-lymphocytes</th>
<th>B-lymphocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intact WBC</td>
<td>9.2x10⁵</td>
<td>2.4x10⁵</td>
<td>2.0x10⁵</td>
<td>2.1x10⁶</td>
<td>1.6x10⁶</td>
</tr>
<tr>
<td></td>
<td>+/- 1.4x10⁵</td>
<td>+/- 0.7x10⁵</td>
<td>+/- 0.4x10⁵</td>
<td>+/- 0.8x10⁶</td>
<td>+/- 0.3x10⁶</td>
</tr>
<tr>
<td>Neutropenic</td>
<td>0.6x10⁵</td>
<td>3.1x10⁵</td>
<td>1.9x10⁵</td>
<td>2.2x10⁶</td>
<td>1.9x10⁶</td>
</tr>
<tr>
<td></td>
<td>+/- 0.2x10⁵</td>
<td>+/- 0.5x10⁵</td>
<td>+/- 0.7x10⁵</td>
<td>+/- 0.4x10⁶</td>
<td>+/- 0.4x10⁶</td>
</tr>
<tr>
<td>p-value</td>
<td>0.001</td>
<td>0.652</td>
<td>0.905</td>
<td>0.920</td>
<td>0.843</td>
</tr>
</tbody>
</table>